Comparing InfuSystem (NYSE:INFU) and Perspective Therapeutics (NYSE:CATX)

Perspective Therapeutics (NYSE:CATX) and InfuSystem (NYSE:INFU) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Risk & Volatility

Perspective Therapeutics has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500. Comparatively, InfuSystem has a beta of 1.81, meaning that its share price is 81% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Perspective Therapeutics and InfuSystem, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perspective Therapeutics	0	1	7	3	3.18
InfuSystem	0	0	0	3	4.00

Perspective Therapeutics presently has a consensus price target of $12.5556, suggesting a potential upside of 229.54%. InfuSystem has a consensus price target of $12.50, suggesting a potential upside of 34.12%. Given Perspective Therapeutics’ higher possible upside, research analysts clearly believe Perspective Therapeutics is more favorable than InfuSystem.

Profitability

This table compares Perspective Therapeutics and InfuSystem’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Perspective Therapeutics	-4,096.66%	-27.40%	-23.16%
InfuSystem	1.12%	2.78%	1.41%

Valuation & Earnings

This table compares Perspective Therapeutics and InfuSystem”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perspective Therapeutics	N/A	N/A	-$46.51 million	N/A	N/A
InfuSystem	$139.89 million	1.36	$870,000.00	$0.23	40.52

InfuSystem has higher revenue and earnings than Perspective Therapeutics.

Institutional & Insider Ownership

54.7% of Perspective Therapeutics shares are owned by institutional investors. Comparatively, 71.1% of InfuSystem shares are owned by institutional investors. 3.5% of Perspective Therapeutics shares are owned by company insiders. Comparatively, 11.4% of InfuSystem shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

InfuSystem beats Perspective Therapeutics on 9 of the 11 factors compared between the two stocks.

About Perspective Therapeutics

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

About InfuSystem

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.